and the future course of the economy. It seems logical that physicians should use the computer to predict the course of blood glucose, particularly as a function of specific therapies that they have in hand. Yet, the proportion of clinicians who use this technology is virtually nil. Why?
Certainly, it is not for a lac< of mathematical or computer models of glucoregulstion. A plethora of such models has preceded the Berger and Rodbard model described in this issue (p. 725) . Over 50 models were published in the 1970s alone. An appropriate perspective regarding the potential usefulness of the Berger and Rodbard model can be obtained by examining why previous models have had little impact on the clinical management of diabetes.
Previous models were either overly simple or excessively complex. Oversimplified models failed to include all of the relationships necessary to account for the known interactions between glucose and insulin. For example, in some models, insulin secretion was incorrectly represented as being directly proportional to plasma glucose or to the rate of change of glucose. In other models, insulin action was assumed to be proportional to plasma insulin rather than to interstitial insulin. Models with major inaccuracies due to oversimplification cannot adequately represent glucose and insulin relationships under even the simplest conditions of oral or intravenous glucose tolerance tests, which are inadequate to describe day-to-day glucose regulation.
At the other end of the spectrum are models that are overly complex. These models include all the known relationships among relevant tissues, hormones, and substrates. For example, all counterregulatory hormones would be included, as would minor interactions such as the effects of free fatty acids on insulin secretion. Although experimentally demonstrable, such minor interactions may not be important determinants of meal-to-meal variations in glucose and insulin. Imbedded in complex models are many coefficients (parameters) that cannot be known with any degree of accuracy. These complex models can be used to describe almost any pattern of glucose and insulin but provide little information about the processes that determine these patterns. They are of limited usefulness in predicting how alterations in therapy will affect blood glucose.
The model presented by Berger and Rodbard represents a compromise between simplicity and complexity. The authors are to be commended for following a disciplined path in developing a minimal model, i.e., a simple model that can fully describe known glucose and insulin relationships. By focusing on patients with insulin-dependent diabetes mellitus (IDDM), they have been able to represent the appearance of insulin in terms of subcutaneous absorption, thereby avoiding the complexities of representing endogenous insulin secretion into the portal circulation. The kinetics of subcutaneous insulin absorption are well studied and simple in comparison with endogenous insulin kinetics. In most clinical situations, without access to glucose-tracer data, it is problematic to differentiate between glucose appearance via gastrointestinal absorption and glucose production by the liver. Thus, Berger and Rodbard have combined (lumped) these two sources of glucose. Finally, they provided a model designed for a single use: the prediction of plasma glucose patterns based on the pattern of exogenous insulin administration. All of these factors allowed them to develop a simple model that appears to adequately describe meal-to-meal insulin and glucose relationships.
Fundamental to the clinical application of Berger and Rodbard's model will be the demonstration that the model is a valid representation of glucose and insulin dynamics in patients. The lack of impact of past models on clinical diabetes care relates to a paucity of serious efforts to validate them. Validation is an essential element in the acceptance of models by both the research and clinical communities. The Berger and Rodbard article begs for a serious, well-planned validation effort. The authors comment that "systemic verification with clinical data would be extremely difficult to perform." However, it is our judgment that the absence of carefully designed validation protocols would jeopardize the life span of this effort, possibly relegating the model to the status of a "flash in the pan" when it could have been a sumptuous banquet. During the course of model validation, certain model assumptions must be carefully examined. Among these are the importance of circulating insulin antibodies, the constancy of insulin kinetics in IDDM patients, and whether insulin transport into the interstitium is normal in patients with IDDM. Berger and Rodbard have the opportunity to directly test the ability of their simulations to predict plasma glucose under various conditions, including those that vary insulin regimens and meal times. Such testing will lead either to widespread acceptance of this model as a clinical tool or to the identification of errors in the model, which would then be subject to improvement by altering the existing model.
It is important to consider the potential uses of this model once it has been validated. Currently, Berger and Rodbard have used the model to simulate blood glucose patterns. That is, they have used parameters extracted from previous publications and have demonstrated the model's ability to account for day-to-day plasma glucose kinetics with a particular stereotypical combination of meal sequence and insulin injection. Having done this, they simply altered the input into the model (i.e., the therapeutic insulin protocol) and predicted the effects of this maneuver on blood glucose patterns. This particular use of the model should prove to be an important educational tool for teaching diabetes therapy. In this regard, Berger and Rodbard make programs available to nascent diabetes hackers to try their own protocols and meal patterns. In addition, the model may be used to predict the effects of alterations in insulin and/or diet therapy in individuals once model parameters have been determined from measured insulin and glucose data. This should prove to be one of the most important clinical applications of this or similar models.
A second potential use of the model would be for identification purposes. Although simulations use assumed parameters to predict insulin and glucose, identification uses measured insulin and glucose data to determine model parameters in individual patients. The parameters then reveal important information about how insulin and glucose interact in vivo. For example, recorded glucose and insulin measurements from individual patients with IDDM could be used to determine insulin sensitivity and insulin absorption kinetics. Such an approach would provide a powerful tool for establishing the metabolic status of a patient. We have used a similar approach to assess (3-cell function and insulin sensitivity from intravenous glucose tolerance test data. Ultimately, the model may be used to design optimal therapeutic regimens. Although current use of the model in simulations allows for testing the effects of various therapeutic regimens, an ideal regimen will be identified only if the person operating the model is clever enough to select the ideal regimen by trial and error. Alternatively, modern theories of optimal input design based on this model can be used to design optimal therapeutic regimens while avoiding the trial-and-error approach.
Mathematical analysis of complex systems with computer technology has revolutionized many aspects of biologic science. The application of this technology to the clinical care of diabetic patients is still in its infancy but holds great promise as a tool for understanding problems that are too complex for solution by human intuition and clinical experience alone. The continued development of models, such as that of Berger and Rodbard, and the testing and application of those models in clinical settings may revolutionize our ability to regulate blood glucose levels in patients with diabetes.
